ArticleFrontiers in medicine2025
Effect of Danlu capsules for the treatment of breast hyperplasia with mastalgia: a multicenter, double-blind, randomized controlled trial protocol.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mastalgia is a prevalent condition among women. Conservative treatment is initially recommended, and tamoxifen is considered a second-line option, but it can cause menopausal-like symptoms. Chinese patent medications are proposed as alternatives, yet evidence remains insufficient. Danlu capsules, which are recommended in certain clinical practice guidelines for breast hyperplasia in China, have demonstrated therapeutic effects on breast pain. However, high-quality randomized controlled trials are lacking to clarify Danlu capsules' efficacy in treating breast pain. This study aims to examine the effectiveness and safety of Danlu capsules for the treatment of mastalgia. Methods: This study is a multicenter, randomized, double-blind, placebo-controlled, and superiority clinical trial involving 264 participants, which will be randomly assigned in a 1:1 ratio to either receive Danlu capsule or placebo via a centralized system. All participants will undergo an eight-week treatment period and an additional 4 weeks of follow-up. The primary outcome will be the breast pain assessed using the visual analog scale (VAS). Secondary outcomes will include the evaluation of the quality-of-life questionnaire, the self-rating anxiety questionnaire, and the self-rating depression questionnaire. Safety monitoring and adverse event recording will be implemented throughout the study. Efficacy will be assessed through covariance analysis for primary endpoints and t-tests for secondary outcomes, with mixed models for repeated measures comparing breast pain VAS score changes at weeks 4, 8, and 12. All statistical analyses will be conducted using SAS (9.4), and no interim analyses will be performed. Discussion: This trial will evaluate the clinical efficacy and safety of Danlu capsules in treating breast hyperplasia with mastalgia. The findings are expected to provide an evidence-based treatment option supporting the potential role of Chinese patent medicine in the management of breast pain. Clinical trial registration: http://itmctr.ccebtcm.org.cn/, ITMCTR2025000715.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.